Our findings showed that AML cells with FLT3 internaltandem duplication (ITD) mutations, an alteration in the FLT3 geneencoding a tyrosine kinase involved in cell growth and survival signalingpathways, exhibited the most favorable responses to this series ofMTHFD2 inhibitors. This evidence concerns the gene FLT3 and acute myeloid leukemia.